Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2.

ABSTRACT: The COVID-19 pandemic caused by SARS-CoV-2 has emerged as a global catastrophe. The virus requires main protease for processing the viral polyproteins PP1A and PP1AB translated from the viral RNA. In search of a quick, safe and successful therapeutic agent; we screened various clinically approved drugs for the in-vitro inhibitory effect on 3CL^Pro which may be able to halt virus replication. The methods used includes protease activity assay, fluorescence quenching, surface plasmon resonance (SPR), Thermofluor® Assay, Size exclusion chromatography and in-silico docking studies. We found that Teicoplanin as most effective drug with IC₅₀ ~ 1.5 μM. Additionally, through fluorescence quenching Stern-Volmer quenching constant (K_SV) for Teicoplanin was estimated as

SUBMITTER: Tripathi PK 

PROVIDER: S-EPMC7444494 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature